Stevens Capital Management LP Acquires Shares of 42,503 Hims & Hers Health, Inc. $HIMS

Stevens Capital Management LP bought a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the 3rd quarter, Holdings Channel.com reports. The institutional investor bought 42,503 shares of the company’s stock, valued at approximately $2,411,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Quent Capital LLC bought a new position in Hims & Hers Health in the 3rd quarter worth approximately $28,000. Virtus Advisers LLC bought a new stake in Hims & Hers Health during the 2nd quarter valued at $26,000. Quaker Wealth Management LLC purchased a new stake in shares of Hims & Hers Health during the second quarter worth $29,000. Bessemer Group Inc. boosted its holdings in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after acquiring an additional 312 shares during the period. Finally, Hilltop National Bank purchased a new position in shares of Hims & Hers Health in the third quarter valued at $35,000. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

HIMS has been the topic of a number of recent research reports. Zacks Research cut Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday, January 19th. Leerink Partners raised shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Barclays started coverage on shares of Hims & Hers Health in a research report on Monday, December 8th. They issued an “overweight” rating and a $48.00 price objective for the company. UBS Group set a $32.00 target price on shares of Hims & Hers Health in a report on Tuesday, November 4th. Finally, Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $39.32.

Hims & Hers Health Stock Down 1.2%

Shares of NYSE HIMS opened at $15.62 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The business has a 50-day moving average of $28.63 and a 200-day moving average of $40.45. The firm has a market capitalization of $3.56 billion, a price-to-earnings ratio of 28.93, a PEG ratio of 2.95 and a beta of 2.43. Hims & Hers Health, Inc. has a 12 month low of $15.29 and a 12 month high of $70.43.

Hims & Hers Health declared that its Board of Directors has approved a stock repurchase plan on Monday, November 17th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 3% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In related news, CFO Oluyemi Okupe sold 23,090 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $35.72, for a total value of $824,774.80. Following the completion of the transaction, the chief financial officer directly owned 94,333 shares in the company, valued at approximately $3,369,574.76. The trade was a 19.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Chi sold 13,750 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $504,762.50. Following the completion of the transaction, the chief operating officer directly owned 305,161 shares in the company, valued at approximately $11,202,460.31. This represents a 4.31% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 82,963 shares of company stock worth $2,944,621. 13.71% of the stock is owned by corporate insiders.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Acquisition expands international footprint and revenue run‑rate — Hims & Hers agreed to buy Australian digital‑health provider Eucalyptus in a deal worth up to $1.15 billion, a move management says will accelerate global growth and add a high‑growth revenue stream. Hims & Hers Health to acquire Australia’s Eucalyptus for up to $1.15 billion
• Positive Sentiment: Deal expected to materially increase top line and international scale — Coverage notes Eucalyptus brings ~ $450M of annual revenue growing at triple‑digit rates and should accelerate HIMS’ personalized care footprint outside the U.S. Hims & Hers HUGE Acquisition News!
• Positive Sentiment: Product/technology expansion — Hims is ramping AI‑driven preventive care (menopause, low testosterone, multi‑cancer testing and deeper personalization), which supports a higher‑value platform positioning longer term. Hims & Hers Accelerates AI Preventive Care and Platform Strategy
• Neutral Sentiment: Analysts flag mixed near‑term earnings implications — Some previews say platform strength and new specialties could help Q4 results, but recognize higher costs tied to deals and expansion may cloud near‑term profitability. Can Platform Strength Support Hims & Hers Stock Before Q4 Earnings?
• Negative Sentiment: Regulatory and legal scrutiny around GLP‑1/weight‑loss products — Coverage reports the company’s earlier GLP‑1/compounder strategy drew backlash from drugmakers and regulators, raising compliance, litigation and reputational risks that could hurt sales and margins. Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders
• Negative Sentiment: Reputational headlines and legal risk over “copycat” weight‑loss drugs — Media coverage and analysis highlight mounting criticism that could pressure demand or invite enforcement actions. Hims & Hers under fire over copycat weight loss drugs
• Neutral Sentiment: Deal financing and integration risk — Commentators note HIMS will use significant cash (and potentially other consideration) for the deal, raising questions about near‑term balance sheet flexibility and execution risk on integrating Eucalyptus. Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.